Connor, Martin J.Genie, MesfinDudderidge, TimWu, HangjianSukumar, JohannaBeresford, MarkBianchini, DilettaGoh, CheeHoran, GailInnominato, PasqualeKhoo, VincentKlimowska-Nassar, NataliaMadaan, SanjeevMangar, StephenMcCracken, StuartOstler, PeterPaisey, SangeetaRobinson, AngusRai, BhavanSarwar, NaveedSrihari, NarayananJayaprakash, Kamal ThippuVarughese, MohiniWinkler, MathiasAhmed, Hashim U.Watson, VerityIP5-MATTER Trial Investigators2025-10-302025-06Connor, M J, Genie, M, Dudderidge, T, Wu, H, Sukumar, J, Beresford, M, Bianchini, D, Goh, C, Horan, G, Innominato, P, Khoo, V, Klimowska-Nassar, N, Madaan, S, Mangar, S, McCracken, S, Ostler, P, Paisey, S, Robinson, A, Rai, B, Sarwar, N, Srihari, N, Jayaprakash, K T, Varughese, M, Winkler, M, Ahmed, H U, Watson, V & IP5-MATTER Trial Investigators 2025, 'Patients' Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer : The IP5-MATTER Study', European Urology Oncology, vol. 8, no. 3, pp. 663-673. https://doi.org/10.1016/j.euo.2024.06.0102588-9311ORCID: /0000-0002-1744-4666/work/195920489https://hdl.handle.net/2164/26336We would like to thank all the participants, study principal investigators, trial clinicians, research nurses, Imperial Clinical Trial Unit staff, NIHR Clinical Research Network (CRN) Portfolio, and other site staff who were responsible for set-up, recruitment, and delivery of the IP5-MATTER study. We are also grateful for the support of the trial management group and our patient representatives. We would also like to thank our trial funders the Wellcome Trust and University College London Hospitals (UCLH) Charity. Finally, we would like to thank Dr. Luis Loria Rebolledo for his advice on statistical modelling. IP5-MATTER Trial Investigators: Nicholas Temple (trial patient representative, Imperial College London); Ms. Natalia Klimowska-Nassar and Mr. Feargus Hosking-Jervis (Imperial College Clinical Trials Unit, Imperial College London); Dr. Alison Falconer and Dr. Michael Gonzalez (Charing Cross Hospital, Imperial College Healthcare NHS Trust); Professor Matin Sheriff (Medway Maritime Hospital); Ms. Deborah Kemp (Sunderland Royal Hospital); Professor Iqball Shergill (Betsi Cadwaladr University Health Board, Wrexham Maelor Hospital); Ms. Lesley Harden (The Royal Surrey County Hospital); Ms Nikki Carney (University Hospital Southampton), Dr. Saheel Mukhtar (East Surrey Hospital); Dr. Duncan Wheatly (The Royal Cornwall Hospital); Dr. Denise Sheehan and Mr. John McGrath (The Royal Devon and Exeter Hospital); Dr. Alison Reid (Kingston Hospital); Dr. Anna Bowzykal Al-Naeeb (Bedford Hospital); Dr. Susannah Brock (University Hospitals Dorset NHS Foundation Trust); Ms. Ling Lee (The Royal Bolton Hospital); Dr. Dakshinamoorthy Muthu Kumar (East Suffolk and North Essex NHS Foundation Trust); Dr. Sanjay Dixit (Grimsby Hospital, Diana Princess of Wales); and Dr. Milan Anjanappa (Luton and Dunstable Hospital). Additional information: N. Temple, our patient representative for the IP5-MATTER trial, died in 2023.111332156engSDG 3 - Good Health and Well-beingCryotherapyCytoreductiveDiscrete choice experimentMetastasis-directed therapyMetastatic prostate cancerOligometastatic diseasePatient preferenceRadical prostatectomyRadiotherapyStereotactic ablative body radiotherapyRC0254 Neoplasms. Tumors. Oncology (including Cancer)General MedicineRC0254Journal article10.1016/j.euo.2024.06.010http://www.scopus.com/inward/record.url?scp=105008082558&partnerID=8YFLogxK